Commentary Open Access
Volume 1 | Issue 1 | DOI: https://doi.org/10.33696/Gastroenterology.1.005
The Potential Role of SEPT6 in Liver Fibrosis and Human Hepatocellular Carcinoma
Yuhui Fan1,2,3,*, Mei Liu3,*
- 1Department of Medicine II, Liver Center Munich, University Hospital, Ludwig-Maximilians-University of Munich, Munich, Germany
- 2Comprehensive Cancer Center München TUM, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany
- 3Institute of Liver and Gastrointestinal Diseases, Department of Gastroenterology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China
Corresponding Author
Yuhui Fan, fanyuhui123@126.com
Mei Liu, TJliumei@yeah.net
Received Date: May 19, 2020
Accepted Date: May 26, 2020
Fan Y, Liu M. The Potential Role of SEPT6 in Liver Fibrosis and Human Hepatocellular Carcinoma. Arch Gastroenterol Res. 2020; 1(1): 22-25.
Copyright: © 2020 Fan Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Evaluation and Management of chronic Hypertension in Pregnancy
Chronic hypertension is present in 1-2% of pregnant women. Women with chronic hypertension are at an increased risk of maternal and perinatal complications when compared with normotensive women.
Pharmacologic Therapy with Niacin for Nonalcoholic Fatty Liver Disease (NAFLD): Emerging Evidence
In pharmacologic doses niacin (nicotinic acid) has been used clinically for over six decades for atherogenic dyslipidemia and reduction of cardiovascular event risk. In combination with statin therapy, it effects regression of coronary atherosclerosis. Emerging evidence indicates a new potential use for niacin for the treatment of NAFLD and its complications. Despite this enormous amount of data on niacin, there is confusion and misconceptions about its use of a drug rather than as a vitamin, its formulations, and how it can be used in clinical practice. The purpose of this invited brief communication is to update and summarize this emerging evidence. We comment on how it may be valuable in the context of other drugs-in-development for NAFLD, especially for combination therapy for synergistic efficacy.
Alcoholic Liver Disease and the co-triggering Role of MEOS with Its CYP 2E1 Catalytic Cycle and ROS
Until the early sixties, the concept prevailed that alcoholic liver disease (ALD), also termed alcohol-related liver disease (ARLD), results from malnutrition commonly observed among individuals consuming chronically high amounts of alcohol rather than being causally related to the use of alcoholic beverages. However, the malnutrition concept became a matter of debate because of the clinical observation that humans, even on a normal diet and without signs of underweight or malnutrition
Obeticholic Acid, FXR Agonists, Liver Disease and Plasma Biomarkers
How medications whose major biologic effect is to reduce bile acid synthesis favorably affect the course of a variety of cholestatic and metabolic liver diseases is not immediately apparent. Also, the most frequently used plasma biomarkers for evaluating benefit, alkaline phosphatase and conjugated bilirubin [1], provide different information. The former may be misleading with respect to the course of the disease and therefore it is important to focus on the pathophysiologic basis for its use.
Commentary on: Echocardiography in Pulmonary Arterial Hypertension: Is It Time to Reconsider Its Prognostic Utility?
Pulmonary Arterial Hypertension (PAH) represents a rare but devastating disease due to small pulmonary arterial vessels remodelling and increased pulmonary vascular resistance leading to right ventricular dysfunction, right heart failure and death.